American College of Cardiology

APRIL 8, 2024

Treatment with AT-001, a highly selective aldose reductase inhibitor, had no significant effect on exercise capacity as measured by peak oxygen uptake (VO2) among individuals with diabetic cardiomyopathy (DbCM), according to results from a Late-Breaking Clinical Trial.

Exercise 51

Exercise Cardiomyopathy Diabetes Article 51

Heart BMJ

APRIL 25, 2024

Clinical introduction A patient in his 60s with a history of ischaemic cardiomyopathy and severely reduced left ventricular ejection fraction of 20% presents with worsening dyspnoea on exertion. mL/kg/min) despite maximal effort. The test was stopped due to shortness of breath. Plots 1 and 2 from the CPET are shown in figure 1A and B.

Exercise 52

Exercise Cardiomyopathy Defibrillator 52

American Heart News - Heart News

MAY 8, 2024

WASHINGTON and DALLAS (May 8, 2024) – The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM).

Cardiomyopathy 64

Cardiomyopathy Exercise 64

HeartRhythm

OCTOBER 19, 2023

Hypertrophic cardiomyopathy (HCM)-related sudden cardiac death (SCD) rates with contemporary management are low; however, high-intensity exercise can induce fatal arrhythmias in HCM patients. Thus, current guidelines recommend avoiding high-intensity exercise in HCM patients at high risk for SCD1,2.

Exercise 40

Exercise Cardiomyopathy Sudden Cardiac Death Cardiovascular Disease 40

DAIC

JULY 10, 2024

Findings from an observational analysis of ARISE-HF trial participants, newly-published in the Journal of the American College of Cardiology, JACC, shed light on the racial and ethnic disparities in diabetic cardiomyopathy (DbCM), which researchers note may have the potential to inform clinical practice, interventions, and policies.

Cardiomyopathy 113

Cardiomyopathy Diabetes Health Disparities Exercise 113

Physiologically Speaking

FEBRUARY 28, 2024

These numbers indicate rising participation — an increase in people involved in chronic endurance exercise training for the sake of competition and health. We know exercise, and especially a marathon, stresses the heart. ” Isn’t exercise good for us? ” Isn’t exercise good for us? 

Exercise 98

Exercise Sudden Cardiac Death Physiology Congenital 98

Nature Reviews - Cardiology

MAY 27, 2024

Nature Reviews Cardiology, Published online: 28 May 2024; doi:10.1038/s41569-024-01044-8 Data from the SEQUOIA-HCM trial show that aficamten, a cardiac myosin inhibitor, increases exercise capacity and improves quality of life in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cardiomyopathy 64

Cardiomyopathy Quality of Life Exercise 64

American College of Cardiology

JULY 2, 2024

What is the effect of AT-001, an aldose reductase inhibitor, on exercise capacity among individuals with diabetic cardiomyopathy (DbCM) with reduced exercise capacity and at high risk for progression to overt heart failure (HF)?

Cardiomyopathy 51

Cardiomyopathy Diabetes Exercise Heart Failure 51

HeartRhythm

APRIL 30, 2024

Introduction: Pathogenic desmoplakin (DSP) variants are associated with left or biventricular arrhythmogenic cardiomyopathy. Exercise promotes penetrance and sustained ventricular arrhythmias (VA) in classic ARVC. It is unknown if exercise affects risk in DSP variant carriers.

Exercise 40

Exercise Cardiomyopathy Arrhythmia 40

Nature Reviews - Cardiology

APRIL 22, 2024

Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01032-y According to data from the IMPROVE-HCM trial, ninerafaxstat is well tolerated by patients with symptomatic non-obstructive hypertrophic cardiomyopathy and improves exercise performance among those who are most symptomatically limited.

Cardiomyopathy 59

Cardiomyopathy Exercise 59

Frontiers in Cardiovascular Medicine

JANUARY 3, 2024

Hypertrophic cardiomyopathy is the most common genetic cardiac disorder and is defined by the presence of left ventricular (LV) hypertrophy in the absence of a condition capable of producing such a magnitude of hypertrophy. Over the past decade, guidelines on the screening, diagnostic, and management protocols of pediatric primary (i.e.,

Pediatrics 87

Pediatrics Cardiomyopathy Heart Failure Exercise 87

HCPLive

MAY 9, 2024

Compass Pathways reports positive results for psilocybin in PTSD treatment, showing safety and symptom improvement in an open-label phase 2 study.

Exercise 72

Exercise Cardiomyopathy 72

DAIC

APRIL 9, 2024

Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. For more information on hypertrophic cardiomyopathy, visit CardioSmart.org/HCM.

Cardiomyopathy 52

Cardiomyopathy Quality of Life Preserved Ejection Fraction Chest Pain 52

DAIC

MAY 9, 2024

The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM). Ommen, MD, FACC , medical director of the Mayo Hypertrophic Cardiomyopathy Clinic and chair of the guideline writing committee.

Cardiomyopathy 52

Cardiomyopathy Pediatrics Quality of Life Sudden Cardiac Death 52

HeartRhythm

APRIL 30, 2024

Hypertrophic cardiomyopathy (HCM) is associated with a predisposition to lethal ventricular arrhythmias. LGE scar burden on MRI is thought to contribute to this risk, but its impact on electrophysiological substrate is not well understood.

Cardiomyopathy 40

Cardiomyopathy Electrophysiology Exercise Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Autonomic remodeling is known to occur in premature ventricular contraction-induced cardiomyopathy (PVC-CM). However, the functional significance of this finding remains unclear.

Cardiomyopathy 40

Cardiomyopathy Exercise 40

NEJM Journal Watch - Cardiology

MAY 11, 2024

New recommendations include exercise prescription and treatment with cardiac myosin inhibitors.

Cardiomyopathy 80

Cardiomyopathy Exercise 80

The American Journal of Cardiology

SEPTEMBER 21, 2024

Publication date: Available online 20 September 2024 Source: The American Journal of Cardiology Author(s): Agostina M. Fava, Zoran B Popovic, Alaa Alashi, Maran Thamilarasan, Bo Xu, Milind Y.

Exercise 40

Exercise Cardiomyopathy 40

Med Page Today

MAY 13, 2024

(MedPage Today) -- The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean change in the peak oxygen uptake.

Exercise 52

Exercise Cardiomyopathy 52

Circulation: Genomic and Precision Medicine

NOVEMBER 28, 2023

Background:Limiting high-intensity exercise is recommended for patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) due to its association with penetrance, arrhythmias, and structural progression. Guidelines recommend shared decision-making (SDM) for exercise level, but there is little evidence regarding its impact.

Exercise 40

Exercise Cardiomyopathy Arrhythmia Circulation 40

European Journal of Heart Failure

SEPTEMBER 26, 2023

Exercise training in patients with advanced heart failure and left ventricular assist device (Ex-VAD) trial. 6MWT, 6-min walk test; KCCQ, Kansas City Cardiomyopathy Questionnaire physical domain score; peakVO 2 , peak oxygen consumption; RCT, randomized controlled trial. m (95% CI 16.9, p  = 0.0124), both after 12 weeks. m (95% CI 16.9,

Exercise 40

Exercise Heart Failure Quality of Life Cardiomyopathy 40

NEJM Journal Watch - Cardiology

APRIL 30, 2024

The highly selective aldose reductase inhibitor AT-001 did not improve exercise capacity in a randomized trial.

Cardiomyopathy 81

Cardiomyopathy Diabetes Exercise Outcomes 81

Circulation

OCTOBER 19, 2023

BACKGROUND:The consequences of exercise-induced premature ventricular contractions (PVCs) in asymptomatic individuals remain unclear. Low PVC counts during exercise and recovery were both associated with MI/HF/LTVA risk, independently of clinical factors: adjusted hazard ratio (HR), 1.2 (1–5 years; 51.1% years; 51.1%

Exercise 40

Exercise Myocardial Infarction Heart Failure Cardiomyopathy 40

All About Cardiovascular System and Disorders

APRIL 30, 2024

Hypertrophic cardiomyopathy is a genetic disorder with a guarded prognosis which occurs in about 1:500 individuals. The most common symptom of hypertrophic cardiomyopathy is dyspnoea which occurs in 90% of cases and is due to elevated left ventricular diastolic pressures as a consequence of the diastolic dysfunction.

Cardiomyopathy 40

Cardiomyopathy Bicuspid/Mitral Document Arrhythmia 40

Open Heart

JUNE 9, 2022

Background This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heart failure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality.

Quality of Life 52

Quality of Life Cardiac Rehabilitation Exercise Heart Failure 52

NEJM Journal Watch - Cardiology

JUNE 3, 2024

In a manufacturer-funded trial, aficamten improved exercise performance compared with placebo in patients with symptomatic obstructive HCM.

Cardiomyopathy 40

Cardiomyopathy Exercise 40

European Journal of Heart Failure

DECEMBER 22, 2023

Abstract Background and aims In the EXPLORER-HCM trial, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved functional capacity of symptomatic hypertrophic obstructive cardiomyopathy (HOCM) patients.

Cardiomyopathy 40

Cardiomyopathy Pharmacology Atrial Fibrillation Outpatient 40

American College of Cardiology

SEPTEMBER 30, 2024

Treatment with aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) was associated with broad clinical efficacy across multiple outcome domains, including rapid and sustained decreases in outflow gradients, meaningful improvements in functional class and quality of life, enhanced exercise capacity, and significant reductions in (..)

Quality of Life 40

Quality of Life Exercise Cardiomyopathy Outcomes 40

EMS 12-Lead

MAY 20, 2022

She reports a known history of Hypertrophic Cardiomyopathy (HCM) with left ventricular outflow tract obstruction and is on daily beta blocker therapy. Furthermore, she denies any hydration since conclusion of exercise. Diagnosis and management of hypertrophic cardiomyopathy: Expert analysis. References Naidu, S. Tower-Rader, A.

Cardiomyopathy 52

Cardiomyopathy Ischemia STEMI Coronary Angiogram 52

Circulation: Heart Failure

DECEMBER 18, 2023

RESULTS:In hypertrophic cardiomyopathy, RT (estimated marginal mean [95% CI]) was 3.4 (0.4–6.4) mm Hg with exercise (P<0.001). RESULTS:In hypertrophic cardiomyopathy, RT (estimated marginal mean [95% CI]) was 3.4 (0.4–6.4) mm Hg with exercise (P<0.001). mm Hg, increasing to 18.5 mm Hg, increasing to 18.5

Preserved Ejection Fraction 40

Preserved Ejection Fraction Exercise Cardiomyopathy Heart Failure 40

Heart BMJ

MAY 10, 2024

Objective The objective is to evaluate the 5-year follow-up results of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) for hypertrophic obstructive cardiomyopathy (HOCM), including clinical status, electrocardiographic and echocardiographic characteristics. mm Hg, p<0.001; post exercise: from 130.5

Ablation 52

Ablation Exercise Heart Failure Cardiomyopathy 52

All About Cardiovascular System and Disorders

MAY 2, 2024

During aerobic exercise which is isotonic, the heart rate and stroke volume increases. Isometric exercise or weight training on the other hand causes only slight increase in cardiac output due to increase in heart rate. Effect of exercise on right ventricle. J point elevation and early repolarization pattern has been reported.

Exercise 40

Exercise Cardiomyopathy Blood Pressure Physiology 40

DAIC

APRIL 9, 2024

Decline in exercise ability is a hallmark of progression to overt heart failure. The international ARISE-HF trial was designed to test the effectiveness of the investigational drug AT-001 at stabilizing exercise capacity in patients with diabetic cardiomyopathy.

Heart Failure 52

Heart Failure Diabetes Cardiomyopathy Exercise 52

DAIC

MAY 6, 2024

Patients who transitioned to the oral daily formulation after a lengthy treatment with the weekly IV formulation improved further in this assessment of exercise tolerance, which is the primary endpoint of the ongoing Phase 3 LEVEL study. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

DAIC

OCTOBER 2, 2024

Director of the Hypertrophic Cardiomyopathy Center at the Lahey Hospital and Medical Center. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. 30, 2024 — Cytokinetics, Inc.

Cardiomyopathy 52

Cardiomyopathy Sudden Cardiac Death Biomarkers Heart Failure 52

CardiacWire

JANUARY 3, 2024

Topline results from Cytokinetics’ SEQUOIA-HCM phase 3 trial suggest that 2024 could be the company’s best year ever, showing that its investigative obstructive hypertrophic cardiomyopathy (HCM) drug aficamten significantly improved all primary and secondary endpoints. mL/kg/min (the primary endpoint).

Exercise 64

Exercise Cardiomyopathy Heart Failure 64

DAIC

MAY 31, 2024

Given the rapid expansion of sports cardiology, cardiovascular care teams must understand contemporary care and practice management strategies for all athletes—from the elite to the exercise enthusiast.

Cardiac Arrest 111

Cardiac Arrest Exercise Thrombosis Diet 111